Lower brain activity in one area linked to MS risk

Credibility

Interest

Share:1 min read

Key Takeaway

Lower activity in one brain area was linked to a higher risk of MS.

What They Found

Lower activity in one area deep in the brain was linked to higher MS risk. Activity in another brain area was linked to higher lupus risk. Activity on the left and right sides of a brain structure showed opposite links to a blood vessel disease. Fibromyalgia was linked to lower activity in part of the brain that helps coordinate movement. The researchers used genetic data to study these links, but they did not test a treatment.

Who Should Care and Why

The study used genetic and brain scan data, including brain scan data from 8,428 people. It examined links between brain activity and 18 diseases, including MS. For people with MS, the main finding was a link between lower activity in one brain area and higher MS risk. The researchers also reported findings for lupus, a blood vessel disease, and fibromyalgia. These findings concern the chance of developing MS, not symptoms or changes after diagnosis.

Important Considerations

You should know this was a study of genetic and brain scan data, not a treatment trial. The abstract gives 8,428 people for the brain scan data but does not give a count for every disease group. One finding about the blood vessel disease had limited evidence, and the study does not show that changing brain activity prevents MS.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research

Article Topics:

Mendelian randomizationautoimmune inflammatory diseasesbrain functional networksdouble machine learningimaging‐derived phenotype

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Advanced science (Weinheim, Baden-Wurttemberg, Germany) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News